Banu ÖZTÜRK, Türker TAŞLIYURT, Faruk KUTLUTÜRK, Berna YELKEN, Şafak ŞAHİN

Relationship between N -terminal pro B-type natriuretic peptide and body mass index

Amaç: N -terminal pro B -tip natriüretik peptid (NT-proBNP) hacim genişlemesinde yanıt olarak kardiyak ventriküllerden salgılanır. Natriüretik peptid üzerine obez itenin etkisi henüz tam olarak aydınlatılmış değildir. Buçalışmada normal kilolu ve obez bireylerde NT-proBNP düzeylerinin karşılaştırılması amaçlandı.Yöntem: Çalışmaya kırkiki obez hasta (37 kadın, 5erkek; vücut kitle indeksi ≥ 30) ve normal kilolu otu zbeş kişi (27 kadın, 8 erkek; vücut kitle indeksi ≤ 25)kontrol grubu olarak alındı. Hasta ve kontrol grubununNT-pro BNP düzeyleri karşılaştırıldı.Bulgular: NT-pro BNP düzeyleri obez hastalarda kontrol grubuna göre anlamlı olarak yüksek bulundu(p=0.027). Vücut kitle indeksi ile NT-pro BNP arasındakorelasyon yoktu. Obez hastalarda sistolik ve diyastolikkan basınçları istatistiksel olarak yüksekti (sırasıyla; p

N- terminal pro B-tip natriüretik peptit ve vücut kitle indeksi arasındaki ilişki

Objective : N -terminal pr o B -type natriuretic pe ptide (NT-pro BNP) is secreted from the cardiac ventric les in response to volume expansion. The effect of obesity on natriuretic peptide has yet to be fully elucidated. We aimed to compare the NT-pro BNP levels in obese and in healthy individuals with normal body mass index. Method: Forty -two obese patients (37 women, 5 men; body mass index ≥ 30) and thirty -five normal body mass index individuals (27 women, 8 men; body mass index ≤ 25) were analyzed regarding NT-pro BNP.Results: The serum levels of NT-pro BNP was signifi- cantly higher in obese patients than normal body mass index individuals (p=0,027). No correlation was found between body mass index and NT-pro BNP. Statistica lly significant difference was found between systolic and diastolic blood pressures in both groups (p

PDF

___

1. Kenchaiah S, Evans JC, Levy Wilson PW, Benja min EJ, Larson MG, Kannel WB, Vassan RS, Obesity and the risk of heart failure. N Engl J Med. 2002; 347:305 -13
2. Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geom etry JAMA 1991; 266:231 -6
3. Reisin E, Messerli FH. Obesity -related hyperte nsion: mechanisms, cardiovascular risks, and h e redity. Curr Opin Nephrol Hyperten 1995; 4:67 -71
4. Rocchini AP, Moorehead CP, DeRemer S, Bondie D. Pathogenesis of weight related changes in blood pressure in dogs. Hypertension 1989; 13:922 -8
5. Rocchini AP. Insulin resistance and blood pre s sure regulation in obese and non -obese subjects. Hype rtension 1991; 17: 837 -42
6. Rocchini AP, Key S, Bondie D. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescent. N Engl J Med 1989; 321: 580 -5
7. Levin ER, Gardner DG, Samson WK. Natriuretic pe ptids. N Engl J Med 1998; 339: 312 -28
8. Schirmer H, Omland T. Circulating N -terminal pro atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general popul ation. The Tromso Study. Eur Heart J. 1999; 20: 755 -63
9. Lerman A, Gibbons RJ, Rodeheffer RJ, McKinley LJ, Heublein DM, Burnett JC Jr. Circulating N -terminal atrial natriuretic peptide as a marker for symptom less left-ventricular dysfunction. Lancet 1993; 341: 1105-9
10. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall -Pedoe H, McMurray JJ, Dargie HJ. Biochemical detection of left ventricular systol ic dysfunction. Lancet 1998; 351: 9 -13.
11. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thom pson SG, Poole -Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in pri mary care. Lancet 1997; 350: 1349-53
12. Messerli FH, Ventura HO, Reisin E, Dreslinski GR, Dunn FG, MacPhee AA, Frohlich ED. Borderline hype rtension and obesity: two prehypertensivestate with elevated cardiac output. Ci rculation. 1982; 66: 55 -60
13. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, Sutherland P, Omland T, Vasan RS. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90:254 -8
14. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity o plasma n atriuretic peptide levels. Circulation 2004; 109:594 -600
15. Licata G, Volpe M, Scaglione R, Rubattu S. Saltregulating hormones in young normotensive obese subjects of saline load. Hypertension. 1994; 23: 120 -4
16. Sarzani R, Dessi -Fulgheri P, Paci VM, Espinosa E, Ra ppe lli A. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol I n vest. 1996; 19: 581 -5
17. Sarzani R, Dessi -Fulgheri P, Salvi F, Serenelli M, Spagnolo D, Cola G, Pupita M, Giantomassi L, Rappelli A. A novel promoter variant of the n a triuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hyperte n sives. J Hypertens. 1999; 17: 1301 -5.
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson DJ, Oparil S, Wright JT, Roccella EJ, and the National High Blood Pressure Education Program Coordinating Commi ttee. The Seventh Report of the Joint National Co mmittee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289: 260 -72
19. Yamamoto, K, Burnett, JC, Jougaski, M, Nish i mura RA, Bailey KR, Saito Y, Nakao K, Redfield MM. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and v entricular hypertro phy Hypertension. 1996; 28: 988 -94
20. Luchner A, Burnett JC, Jr. Jougasaki M, Hense HW, Heid IM, Muders F, Riegger GA, Schunkert H. Evalu ation of brain natriuretic peptide as marker of left ve ntricular dysfunction and hypertrophy in the popul ation J Hypertens. 2000; 18:1121 -8
21. Qi W, Mathisen P, Kjekhus J, Simonsen S, Bjørnerheim R, Endresen K, Hall C. Natriuretic peptides in patients with aortic stenosis Am Heart. 2001; 142:725 -32
22. Packer M, Cohn JN. Consensus recommend a tions for the management of chronic heart failure Am J Card iol. 1999; 83: 1 -32
23. Minami J, Nishikimi T, Ishimitsu T, Makino Y, Kawano Y, Takishita S, Kangawa K, Matsuoka H. Effect of a hypocaloric diet on adrenomedullin and natriuretic peptides in obese patients with essential hypertension J CardiovascPharmacol. 2000; 36: 83 -6
24. Messaoudi L, Donckier J, Stoffel M, Ketelslegers JM, Kolanowski J. Changes in blood pressure and in vas oactive and volume regulatory hormones during semi starvation in obese subjects. Metabolism. 1998; 47: 592-7.
25. Hollister AS, Inagami T. Atrial natriuretic factor and hypertention: a review and metanalysis. Am J Hype rtens. 1991; 4:850 -65.
26. Dessi-Fulgheri P, Palermo R, Di Noto G, Conti V, Bal dinelli A, Pupita G, Agostinelli M, Rappelli A. High levels of plasma atrial natriuretic factor and impaired left ventricular diastolic function in hypertensives witout left ventricular hypertrophy. J Hypertens. 1992; 10: 161-5
27. Ganau A, Devereux RB, Atlas SA, Pecker M, R oman MJ, Vargiu P, Cody RJ, Laragh JH. Plasma atrial natriuretic factor in essential hypertension: relation to ca rdiac size, function and sy s temic hemodynamics. J Am CollCardiol. 1989; 14: 715 -24
28. Hanusch -Enserer U, Hermann KM, Cauza E, Spak M, Mähr B, Dunky A, Rosen HR, Köller U, Prager R. Effect of Gastric Banding on Aminoterminal Pro -brain Natriuretic Peptide in the Morbidly Obese. Obesity Research 2003; 11: 695 8